中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

31 records (took 0.022 seconds)

    Encapsulated cells for hormone replacement therapy
    1.
    发明授权
    Encapsulated cells for hormone replacement therapy 有权
    用于激素替代疗法的封装细胞

    公开(公告)号：US09283251B2

    公开(公告)日：2016-03-15

    申请号：US14002504

    申请日：2012-02-21

    Applicant: Emmanuel Opara ,  James J. Yoo ,  Justin M. Saul ,  Sittadjody Sivanandane ,  Anthony Atala

    Inventor： Emmanuel Opara ,  James J. Yoo ,  Justin M. Saul ,  Sittadjody Sivanandane ,  Anthony Atala

    IPC: A01N63/00 ,  A01N65/00 ,  A61K35/54 ,  A61K31/565 ,  A61K31/57 ,  A61K9/16 ,  A61K9/50

    CPC classification number: A61K35/54 ,  A61K9/167 ,  A61K9/5036 ,  A61K9/5073 ,  A61K31/565 ,  A61K31/57 ,  A61K2300/00

    Abstract: A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition The composition is can be used for estrogen, and optionally also progesterone, delivery, and hence is preferably free or essentially free of oocytes. Methods of using the same and pharmaceutical formulations containing the same are also described.

    Abstract translation: 描述了包含微胶囊的组合物，包含活哺乳动物卵巢颗粒细胞和活哺乳动物卵巢细胞的微胶囊。 在一些实施方案中，颗粒细胞和细胞被包含在组合物中的分离的微胶囊中; 在一些实施方案中，颗粒细胞和细胞在组合物中一起包含在相同的微胶囊中。组合物可用于雌激素，并且任选地也可用于孕酮，递送，因此优选是游离的或基本上不含卵母细胞。 还描述了使用它们的方法和含有它们的药物制剂。

    AGENT FOR TREATING URINARY INCONTINENCE INCLUDING STEM CELLS DERIVED FROM AMNIOTIC FLUID
    3.
    发明申请
    AGENT FOR TREATING URINARY INCONTINENCE INCLUDING STEM CELLS DERIVED FROM AMNIOTIC FLUID 审中-公开
    用于治疗尿毒症的药剂，包括从生物流体中衍生的干细胞

    公开(公告)号：US20140050705A1

    公开(公告)日：2014-02-20

    申请号：US14001149

    申请日：2011-02-25

    Applicant: Jeong Ok Lim ,  Tae Gyun Kwon ,  So Young Chun ,  James J. Yoo

    Inventor： Jeong Ok Lim ,  Tae Gyun Kwon ,  So Young Chun ,  James J. Yoo

    IPC: A61K35/50

    CPC classification number: A61K35/50 ,  A61K9/0019 ,  A61K9/0034 ,  A61K35/34

    Abstract: The present invention relates to a cell therapy product which is intended for regenerating a sphincter muscle and which contains stem cells derived from amniotic fluid, and more particularly, to a cell therapy product which is intended for regenerating the sphincter vesicae and which contains stem cells derived from amniotic fluid. Also, the cell therapy product of the present invention can be provided in the form of a formulation for administration through injection, said formulation being injected into a hydrogel complex to thereby improve the effects thereof. The composition including stem cells derived from amniotic fluid according to the present invention enables stem cells to be differentiated into muscles in the body of individual suffering from urinary incontinence by directly injecting the composition into the individual, thus effectively controlling urinary incontinence by recovering muscle functions. That is, the stem cells derived from amniotic fluid of the present invention are differentiated into muscles in-situ, and the differentiation into muscles can thus be achieved only with cells in order to recover muscle functions.

    Abstract translation: 本发明涉及一种用于再生括约肌的细胞治疗产品，其包含源自羊水的干细胞，更具体地，涉及旨在再生括约肌荚膜的细胞疗法产品，其含有衍生的干细胞 来自羊水 此外，本发明的细胞治疗产品可以以通过注射给药的制剂的形式提供，所述制剂注入水凝胶复合物中，从而改善其效果。 包含根据本发明的源自羊水的干细胞的组合物能够通过将组合物直接注射到个体中使得干细胞能够分化成患有尿失禁的个体的肌肉，从而通过恢复肌肉功能来有效地控制尿失禁。 也就是说，源自本发明的羊水的干细胞原位分化为肌肉，因此可以仅通过细胞实现对肌肉的分化以恢复肌肉功能。

    Metabolic Downregulation for Cell Survival
    4.
    发明申请
    Metabolic Downregulation for Cell Survival 审中-公开
    细胞存活的代谢下调

    公开(公告)号：US20130281400A1

    公开(公告)日：2013-10-24

    申请号：US13882433

    申请日：2011-11-10

    Applicant: James J. Yoo ,  Sang Jin Lee ,  Jaehyun Kim ,  Anthony Atala

    Inventor： James J. Yoo ,  Sang Jin Lee ,  Jaehyun Kim ,  Anthony Atala

    IPC: C12N5/071

    CPC classification number: C12N5/0658 ,  C12N2500/02

    Abstract: The present provides a system and method of maintaining and/or increasing cell viability by downregulating cellular metabolic rate under hypoxic conditions. The present invention also relates to a system and method of prolonging the survival of implanted cells that are under hypoxic condition until host neovascularization is achieved.

    Abstract translation: 本发明提供通过在低氧条件下下调细胞代谢速率来维持和/或增加细胞存活力的系统和方法。 本发明还涉及延长在缺氧条件下进行宿主新生血管形成的植入细胞的存活的系统和方法。

    FREEZING MEDIUM COMPOSITION FOR CRYOPRESERVING AMNIOTIC FLUID-DERIVED STEM CELLS AND A METHOD FOR CRYOPRESERVING THE SAME
    5.
    发明申请
    FREEZING MEDIUM COMPOSITION FOR CRYOPRESERVING AMNIOTIC FLUID-DERIVED STEM CELLS AND A METHOD FOR CRYOPRESERVING THE SAME 审中-公开
    冷冻中和液体衍生干细胞的冷冻中和组合物及其相容化方法

    公开(公告)号：US20130267008A1

    公开(公告)日：2013-10-10

    申请号：US13578972

    申请日：2011-01-14

    Applicant: Yun-Hee Shon ,  James J. Yoo ,  Jang-Soo Suh

    Inventor： Yun-Hee Shon ,  James J. Yoo ,  Jang-Soo Suh

    IPC: C12N5/0735

    CPC classification number: C12N5/0606 ,  A01N1/0221

    Abstract: Provided are to a freezing medium composition for cryopreserving amniotic fluid-derived stem cells, which has A lower concentration of Me2SO and eliminates fetal bovine serum and at the same time does not induce cryoinjury to fluid-derived stem cells and makes it possible to cryopreserve fluid-derived stem cells for a prolonged time using trehalose, sucrose and catalase, and a method for cryopreserving the same. According to the present invention, AFSCs can be cryopreserved with 1/4 the standard Me2SO concentration with the addition of disaccharides, antioxidants and caspase inhibitors. As a result, the use of Me2SO at low concentrations in cell freezing solutions may support the development of clinical trials of AFSCs.

    Abstract translation: 本发明提供一种用于冷冻保存羊水来源的干细胞的冷冻培养基组合物，其具有较低浓度的Me 2 SO并消除胎牛血清，同时不会对流体来源的干细胞诱导冷冻损伤，并且使得可以冷冻保存液体 使用海藻糖，蔗糖和过氧化氢酶的延长时间的干细胞，以及用于冷冻保存的方法。 根据本发明，通过添加二糖，抗氧化剂和胱天蛋白酶抑制剂，AFSC可以用标准Me2SO浓度的1/4冷冻保存。 结果，在细胞冷冻溶液中使用低浓度的Me2SO可能支持AFSC的临床试验的发展。

    SELECTIVE CELL THERAPY FOR THE TREATMENT OF RENAL FAILURE
    7.
    发明申请
    SELECTIVE CELL THERAPY FOR THE TREATMENT OF RENAL FAILURE 审中-公开
    用于治疗失败的选择性细胞治疗

    公开(公告)号：US20080305146A1

    公开(公告)日：2008-12-11

    申请号：US12134813

    申请日：2008-06-06

    Applicant: Anthony Atala ,  James J. Yoo

    Inventor： Anthony Atala ,  James J. Yoo

    IPC: A61F2/00 ,  C12N5/06 ,  A61P7/00 ,  A61K35/12

    CPC classification number: C12N5/0686 ,  A61K9/0024 ,  A61K35/12 ,  A61K35/22 ,  C12N2500/02 ,  C12N2502/256 ,  G01N15/1031 ,  G01N33/56966 ,  G01N2015/0065 ,  G01N2015/1081

    Abstract: Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro. The kidney cells may include peritubular interstitial cells of the kidney, and preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells produce EPO in vivo.

    Abstract translation: 本文提供从肾分化细胞收获的分离的肾细胞群体，其中细胞已经在体外扩增。 肾细胞可以包括肾的肾周间质细胞，并且优选产生促红细胞生成素（EPO）。 也可以基于EPO生产来选择肾细胞。 还提供了产生分离的EPO产生细胞群体的方法，并且提供了在有需要的患者中治疗导致EPO产生减少的肾脏疾病的方法，包括向患者施用群体，由此细胞在体内产生EPO 。

    Medical devices incorporating collagen inhibitors
    9.
    发明授权
    Medical devices incorporating collagen inhibitors 有权
    结合胶原抑制剂的医疗器械

    公开(公告)号：US08883183B2

    公开(公告)日：2014-11-11

    申请号：US12130614

    申请日：2008-05-30

    Applicant: Christopher A. Sullivan ,  Steve J. Hodges ,  Anthony Atala ,  James J. Yoo

    Inventor： Christopher A. Sullivan ,  Steve J. Hodges ,  Anthony Atala ,  James J. Yoo

    IPC: A61F2/00 ,  A61L27/54 ,  A61L29/16 ,  A61L31/16

    CPC classification number: A61K9/7007 ,  A61B17/04 ,  A61F2/02 ,  A61F2/042 ,  A61F2/82 ,  A61K9/0034 ,  A61K9/146 ,  A61K31/517 ,  A61L15/44 ,  A61L17/00 ,  A61L27/54 ,  A61L29/16 ,  A61L31/16 ,  A61L2300/432 ,  Y10S606/907

    Abstract: Provided herein are implantable or insertable biomedical devices comprising a substrate and a collagen inhibitor on or in said substrate, and methods of treatment using the same. In some embodiments, the device is an absorbable esophageal or tracheal stent. In some embodiments, the device is a vascular stent. Wound closure devices are also provided herein, including a substrate and a collagen inhibitor on or in the substrate. Also provided are surgical packings, including a substrate and a collagen inhibitor on or in the substrate. A barrier material for preventing adhesions in a subject is further provided, including a preformed or in situ formable barrier substrate and a collagen inhibitor on or in the substrate. An ointment comprising a collagen inhibitor is further provided. Kits comprising the coated substrates are also provided.

    Abstract translation: 本文提供的是可植入或可插入的生物医学装置，其包含基材和胶原抑制剂在所述底物上或所述底物中，以及使用其的处理方法。 在一些实施例中，该装置是可吸收的食管或气管支架。 在一些实施例中，该装置是血管支架。 本文还提供了伤口闭合装置，其包括衬底上的衬底和胶原抑制剂。 还提供了外科包装，包括底物上的基质和胶原抑制剂。 还提供了用于防止受试者粘连的阻挡材料，其包括在基底上或基底中的预先形成的或原位可形成的屏障底物和胶原抑制剂。 还提供了包含胶原抑制剂的软膏剂。 还提供了包含涂覆的基底的试剂盒。

Patent Agency Ranking